205 related articles for article (PubMed ID: 2248079)
1. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
Da Prada M; Kettler R; Burkard WP; Lorez HP; Haefely W
Acta Psychiatr Scand Suppl; 1990; 360():7-12. PubMed ID: 2248079
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
5. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of moclobemide.
Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
[TBL] [Abstract][Full Text] [Related]
7. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
[TBL] [Abstract][Full Text] [Related]
8. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
[TBL] [Abstract][Full Text] [Related]
9. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
10. [The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].
Andreeva NI; Golovina SM; Faermark MF; Shvarts GIa; Mashkovskiĭ MD
Farmakol Toksikol; 1991; 54(2):38-40. PubMed ID: 1884793
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
[TBL] [Abstract][Full Text] [Related]
12. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB
Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669
[TBL] [Abstract][Full Text] [Related]
13. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
14. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143
[TBL] [Abstract][Full Text] [Related]
15. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
Cusson JR; Goldenberg E; Larochelle P
J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
Simpson GM; Gratz SS
Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
[TBL] [Abstract][Full Text] [Related]
17. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
Da Prada M; Kettler R; Keller HH; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():103-5. PubMed ID: 2248059
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
19. Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats.
Burkard W; d'Agostini F; Kettler R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S35-6. PubMed ID: 1546137
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]